Insider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells 5,515 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis sold 5,515 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $2.97, for a total value of $16,379.55. Following the sale, the executive vice president now owns 83,814 shares of the company’s stock, valued at $248,927.58. The trade was a 6.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Annexon Stock Down 0.7 %

Shares of ANNX opened at $2.81 on Friday. Annexon, Inc. has a 52-week low of $2.63 and a 52-week high of $8.40. The stock has a fifty day simple moving average of $4.26 and a two-hundred day simple moving average of $5.55. The company has a market capitalization of $299.52 million, a PE ratio of -2.68 and a beta of 1.07.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $15.80.

Institutional Investors Weigh In On Annexon

Several hedge funds and other institutional investors have recently bought and sold shares of ANNX. BNP Paribas Financial Markets acquired a new position in Annexon in the 4th quarter valued at about $59,000. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Annexon during the 4th quarter valued at approximately $77,000. E Fund Management Co. Ltd. raised its position in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after buying an additional 4,086 shares during the period. Forefront Analytics LLC lifted its holdings in Annexon by 56.8% in the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after acquiring an additional 5,950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Annexon in the fourth quarter worth approximately $98,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.